15.5
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophi…
Metabolic and excretion pathways eliminate drugs from the body.
Hepatic or renal disorders can impair these pathways, slowing elimination and extending the drug’s half-life.
This prolongs the drug’s duration in the body, increasing the risk of toxicity.
An extended half-life, t1/2, directly prolongs its therapeutic duration, teff, even at the same dose.
In patients with high metabolic or clearance rates, simply increasing the dose may not achieve effective plasma concentrations.
Here, extending the drug’s half-life through chemical modifications or adjunct therapy can help sustain therapeutic plasma levels.
For example, antibiotics such as penicillin are eliminated rapidly. Probenecid is co-administered to competitively inhibit their elimination, enhancing drug efficacy and duration.
Augmentin, a combination of amoxicillin and clavulanic acid uses a similar strategy. Clavulanic acid, a suicide inhibitor of bacterial ꞵ-lactamase, protects amoxicillin from degradation and expands its spectrum against resistant strains.
View the full transcript and gain access to JoVE Core videos
Q1: How does drug elimination affect a medication's half-life and duration in the body?
Drug elimination occurs through hepatic metabolism and renal excretion, which remove drugs from the body. When these pathways function normally, drugs are cleared efficiently. However, impaired liver or kidney function slows elimination, extending the drug's half-life and prolonging its presence in the body, which increases both therapeutic duration and toxicity risk.
Q2: Why does an extended half-life directly increase a drug's therapeutic duration?
An extended half-life (t₁/₂) directly prolongs the drug's effective duration (teff) without requiring a dose increase. When elimination is slowed, the drug remains at therapeutic plasma concentrations longer. This relationship means that manipulating half-life through chemical modifications or co-administered agents can sustain therapeutic levels in patients with high metabolic or clearance rates.
Q3: What is probenecid and how does it enhance antibiotic efficacy?
Probenecid is a co-administered agent that competitively inhibits renal tubular secretion of antibiotics like penicillin and cephalosporin. By slowing their elimination, probenecid extends their half-life and therapeutic duration, enhancing drug efficacy. This strategy is particularly useful for rapidly excreted antibiotics where standard dosing alone cannot maintain adequate plasma concentrations.
Q4: How does clavulanic acid work in Augmentin to expand antibiotic spectrum?
Clavulanic acid acts as a suicide inhibitor of bacterial β-lactamase, an enzyme that degrades β-lactam antibiotics like amoxicillin. By inhibiting this bacterial enzyme, clavulanic acid protects amoxicillin from degradation and expands its antimicrobial spectrum against β-lactamase-producing bacteria, improving treatment efficacy against resistant strains.
Q5: Why is simply increasing the dose insufficient for patients with high drug clearance rates?
Patients with high metabolic or clearance rates rapidly eliminate drugs, making it difficult to achieve and maintain effective plasma concentrations through dose increases alone. Instead, strategies that prolong the drug's half-life—such as structural chemical modifications or co-administration with elimination inhibitors—are more effective at sustaining therapeutic levels and improving clinical outcomes.
Q6: What are the two main pathways through which the body eliminates drugs?
The body eliminates drugs through hepatic metabolism and renal excretion. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms through phase I (modification) and phase II (conjugation) enzymatic processes. Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys, completing the drug elimination process.
Q7: How do hepatic or renal disorders impact drug toxicity risk?
Hepatic or renal disorders impair drug elimination pathways, slowing clearance and extending the drug's half-life. This prolongs the drug's duration in the body, allowing it to accumulate to higher concentrations. Elevated plasma concentrations increase the risk of adverse effects and toxicity, making dose adjustments or alternative therapeutic strategies necessary in patients with compromised liver or kidney function.